Lyon: 5α-Reductase Inhibitors Are Associated with Reduced Risk of SARS-CoV-2 Infection: A Matched-Pair, Registry-Based Analysis [Antiandrogens]

5α-Reductase Inhibitors Are Associated with Reduced Risk of SARS-CoV-2 Infection: A Matched-Pair, Registry-Based Analysis

Lyon et al., Journal of Urology, doi:10.1097/JU.0000000000002180

Lyon et al., 5α-Reductase Inhibitors Are Associated with Reduced Risk of SARS-CoV-2 Infection: A Matched-Pair,.., Journal of Urology, doi:10.1097/JU.0000000000002180

Jan 2022 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 944 5ARI users in the USA and 944 matched controls, showing lower risk of COVID-19 cases with treatment.

Important missing comments or errors? Let us know.

risk of death, 16.9% lower, RR 0.83, p = 0.61, treatment 15 of 944 (1.6%), control 19 of 994 (1.9%), NNT 310.

risk of case, 7.2% lower, RR 0.93, p = 0.04, treatment 399 of 944 (42.3%), control 446 of 994 (44.9%), NNT 38, adjusted per study, odds ratio converted to relative risk, multivariable.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Lyon et al., 31 Jan 2022, retrospective, USA, peer-reviewed, 8 authors, study period 8 March, 2020 - 15 February, 2021.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Antiandrogens All

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit